Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10925153 | 0.95 | HTR2C (0.62) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL19154546 | 0.93 | SMN1; SMN2 (0.54) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL21104613 | 0.91 | HTR2C (0.52) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| Setoperone SCHEMBL9179219 | 0.86 | HTR2C (0.53) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL12794813 | 0.85 | HTR2C (0.62) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL22738408 | 0.85 | HTR2C (0.62) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL6523129 | 0.83 | HTR2A (0.53) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL6523131 | 0.83 | HTR2A (0.53) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL6523137 | 0.83 | HTR2A (0.53) | HTR2CCYP3A4CYP2D6MEN1HTR1A | |
| SCHEMBL10925192 | 0.81 | HTR2C (0.64) | HTR2CCYP3A4CYP2D6MEN1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2024-09-12 | — | — | US | claimed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0070053-B1 | NOVEL BICYCLIC PYRIMIDIN-5-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-16 | — | — | EP | claimed |
| US-4443451-A | PSYCHOTROPIC, ANTIHISTAMINES, ANTISEROTONINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-04-17 | — | — | US | claimed |
| EP-0070053-A2 | Novel bicyclic pyrimidin-5-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2C 5/4885CYP3A4 242/4885CYP2D6 84/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR2C 5/4885CYP3A4 2453/4885CYP2D6 1202/4885 |
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | HTR2C 677/4885CYP3A4 3629/4885CYP2D6 2536/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2C 5/4885CYP3A4 1995/4885CYP2D6 928/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR2C 2/4885CYP3A4 3683/4885CYP2D6 2262/4885 |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | HTR2C 677/4885CYP3A4 3629/4885CYP2D6 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.